April 14, 2022

A Rare (Disease) Opportunity: Amolyt Pharma – Targeting Orphan Diseases of the Endocrine System

A Rare (Disease) Opportunity: Amolyt Pharma – Targeting Orphan Diseases of the Endocrine System

Having focused on endocrine disorders since grad school, first at the bench and later in the board room, Dr. Thierry Abribat founded and became the CEO of EU-based Amolyt Pharma because he wanted to have a “social impact” – he wanted to make a difference. With two clinical stage, biologic assets in hand (and an orphan drug designation) Abribat is hoping to address the serious unmet needs of patients with hypoparathyroidism and acromegaly.